Research programme: indole and indolizine derivatives - Synta
Latest Information Update: 21 Apr 2011
At a glance
- Originator Synta Pharmaceuticals
- Class Indoles; Indolizines
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Cancer; Chronic obstructive pulmonary disease
Most Recent Events
- 21 Apr 2011 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (unspecified route)
- 21 Apr 2011 Discontinued for Asthma in USA (unspecified route)
- 20 Aug 2008 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route)